Adaptive Biotechnologies Corporation (ADPT) Fair Value 2026

ADPT · Diagnostics & Research · 2026-08-27

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-27, Adaptive Biotechnologies Corporation (ADPT) trades at $26.44. QOC: 7.2/10. Value Trap Risk: 25/100 (LOW). 0/13 models active.

Key Facts

Ticker: ADPT
Price: $26.44
Quality Score: 7.2/10
Value Trap Risk: 25/100
Models Active: 0/13
Last Updated: 2026-08-27

Strength: 0 independent models provide multi-angle coverage

Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ADPT?

0 Intrinsic Value Models vs. Current Price ($26.44)

Core Models (Unlocked)
Model	Fair Value	Upside

All Models Active

All 0 models are displayed above.

What Is Adaptive Biotechnologies Corporation (ADPT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Adaptive Biotechnologies Corporation currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ADPT?

0 of 13 models are currently active for ADPT. See which stocks rank higher →

How Does ADPT Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, ADPT ranks #22 by Quality of Company score. CirclFi's QOC score of 7.2/10 evaluates 32 fundamental signals. A score of 7.2 indicates above-average quality.

As a pharmaceutical industry, Adaptive Biotechnologies Corporation operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ADPT should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ADPT a Value Trap?

CirclFi's Value Trap algorithm assigns ADPT a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Adaptive Biotechnologies Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Adaptive Biotechnologies Corporation's fundamental quality profile registers 7.2/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ADPT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Adaptive Biotechnologies Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

CDNACareDx, Inc.QOC 7.3 GHGuardant Health, Inc.QOC 7.0 TWSTTwist Bioscience CorporationQOC 7.4 FLGTFulgent Genetics, Inc.QOC 7.0 CSTLCastle Biosciences, Inc.QOC 7.4 CRLCharles River Laboratories International, Inc.QOC 6.9 BDSXBiodesix, Inc.QOC 6.3 FUNIHypha Labs, Inc.QOC 3.9 DHRDanaher CorporationQOC 8.1 IDXXIDEXX Laboratories, Inc.QOC 9.5 MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: CDNA · GH · TWST · FLGT · CSTL · CRL · BDSX · FUNI · DHR · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to ADPT?

7 companies across all industries closest to ADPT’s Quality of Company score of 7.2/10.

LFSTLifeStance Health Group, Inc.QOC 7.2 NMRKNewmark Group, Inc.QOC 7.2 AFRMAffirm Holdings, Inc.QOC 7.2 HYNEHoyne Bancorp, Inc.QOC 7.2 UTLUnitil CorporationQOC 7.2 SVVSavers Value Village, Inc.QOC 7.2 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LFST · NMRK · AFRM · HYNE · UTL · SVV · NVDA

What Else Do Investors Ask About Adaptive Biotechnologies Corporation’s Valuation?

What is Adaptive Biotechnologies Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Adaptive Biotechnologies Corporation (ADPT). The Quality of Company score is 7.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ADPT overvalued or undervalued right now?

At $26.44, 0 of 0 active models suggest ADPT may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Adaptive Biotechnologies Corporation's business model in Diagnostics & Research.

What does a Quality of Company score of 7.2 mean for ADPT?

Adaptive Biotechnologies Corporation's QOC of 7.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ADPT?

CirclFi analyzes ADPT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ADPT a value trap in 2026?

Adaptive Biotechnologies Corporation's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Adaptive Biotechnologies Corporation (ADPT) a Quality of Company score of 7.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ADPT/ · Methodology

Primary sources for this ADPT valuation

Financial statements: Adaptive Biotechnologies Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001478320) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ADPT as of 2026-08-27; valuations recomputed 2026-08-27.